“Blossom is democratising access to psychedelic research by presenting papers from a broad range of disciplines in an accessible weekly write-up.”
Whether you're scouting the next breakthrough compound, conducting due diligence, or designing a trial, fragmented data creates blind spots. Efficient execution requires seeing the full picture—instantly.
Manual tracking via spreadsheets, relying on stale datasets, and missing critical signals buried in paywalled journals.
A unified intelligence layer. Real-time trial tracking, comprehensive compound landscaping, and expert-vetted insights to de-risk your strategy.
Freshly decoded research, clinical trial updates, and country snapshots pulled directly from the lab to your screen.
Topic overview
Depression is the most studied indication in psychedelic science. Psilocybin is currently in Phase III trials, while ketamine and Spravato offer accessible care today.
Latest paper
This double-blind placebo-controlled randomised clinical trial (n=35) found that a single 25 mg dose of psilocybin, given with psychotherapy, reduced depre...
Latest trial
This Phase II, single-group trial (n=30) will assess group psilocybin-assisted cognitive behavioural therapy for adults with major depressive disorder, wit...
Country snapshot
A global research hub with active trials and pioneering organizations hosting events like ICPR. Despite strict clinical laws, the Netherlands maintains a unique legal status for psilocybin truffles, supporting a world-leading ecosystem.
Timeless reports, compound pages, top research papers lists, and more to help you understand the core concepts of psychedelic science.
Explore the full depth of our intelligence layer. Thousands of datapoints across compounds, people, and markets.
Peer-reviewed literature and summaries.
Interventional and observational studies.
Conferences and gatherings to watch.
Evidence by molecule and safety signals.
Themes connecting research and practice.
Policy and access snapshots by market.
Organizations shaping the field.
Researchers, clinicians, and advocates.
Training and education pathways.
Monthly insights and study summaries.
Stay current on psychedelic research without rebuilding the research desk yourself
Blossom tracks papers, trials, compounds, outcomes, organizations, and regulatory movement so you can find the signal faster.
Solo evidence tracking
For solo researchers, clinicians, and serious readers who need reliable orientation across the field.
USD
per year
$21/mo equivalent
One-year access. No auto-renewal.
Labs, clinics, and diligence teams
For labs, clinics, funds, and small teams that need shared access and faster research workflows.
USD
per year
$83/mo equivalent
Invoice support available for teams.
Pharma, investors, and enterprise teams
For organizations making strategic, clinical, investment, or market-access decisions from psychedelic research intelligence.
USD
per year
annual contract
Bank transfer and invoicing supported.
Students, academic institutions, and nonprofits may qualify for reduced access through the Access Program.
The data you need to make psychedelic treatments accessible.
Watch the launch video
